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Background This study determined whether the naturally attenuated, 
thermotolerant Newcastle disease vaccine virus I-2 could acquire 
virulence after five in vivo passages through SPF chickens. 
Methods Study design was to international requirements including 
European Pharmacopoeia, Ph. Eur., v9.0 04/2013:0450, 2013. I-2 
Working Seed (WS) was compared with five-times-passaged I-2 WS 
(5XP WS) in intracerebral pathogenicity index (ICPI), Fo cleavage site 
sequencing and Safety tests. 
Results The first passage series used a 50% brain: 50% tracheal tissue 
challenge homogenate and was unsuccessful as I-2 was not detected 
after the fourth passage. A second passage series used 10% brain: 
90% tracheal tissue homogenates. I-2 was isolated from tracheal 
tissue in each passage. However harvested titres were below the 
minimum challenge level (107 EID50) specified for the ICPI and Safety 
tests, possibly reflecting I-2’s inherently low pathogenicity 
(interestingly caecal tonsils yielded significant titres). Given this the 
WS and 5XP WS comparisons proceeded. ICPI values were 0.104 and 
0.073 for the WS group and the 5XP WS group respectively confirming 
that I-2, whether passaged or not, expressed low pathogenicity. F0 
amino-acid sequences for both WS and 5XP WS were identified as 112
R-K-Q-G-R-↓-L-I-G119 and so compatible with those of avirulent ND 
viruses. In safety, no abnormal clinical signs were observed in both 
groups except for two chicks in the 5XP WS group, where one bird was 
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withdrawn due to a vent prolapse, and another bird died with 
inconclusive necropsy results. 
Conclusions: These data, the issue of low passage titres with little or 
no virus isolation from brain tissues and the genomic copy approach 
suggest a need to amend Ph. Eur. v9.0 04/2013:0450, 2013 for 
naturally attenuated, low pathogenicity vaccine viruses such as I-
2. From an international regulatory perspective, the study provides 
further definitive data demonstrating that Newcastle disease vaccine 
virus I-2 is safe for use.
Keywords 
Newcastle Disease, I-2; passage, acquired virulence, European 
Pharmacopoeia, village chickens
Peter L.M. Msoffe, Sokoine University of 
Agriculture, Morogoro, Tanzania
3. 
Any reports and responses or comments on the 
article can be found at the end of the article.
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Introduction
Newcastle disease (ND) is one of the most important viral 
diseases of poultry and occurs in both commercial flocks and 
also in scavenging rural (village, backyard, sector 4,) chickens 
(Alders & Spradbrow, 2001; Cattoli et al., 2011; FAO, 2007; 
Spradbrow, 2000). The latter birds contribute significantly 
to the economies of poor households by providing eggs and 
meat for consumption and sale or bartering. These birds also 
are sources of readily available cash and gifts and may also have 
ceremonial or ritual value (Moreki et al., 2011; Perry et al., 
2002; Peters et al., 2012a and Peters et al., 2012b). They 
require the lowest capital investment of any livestock species, 
and have a short production cycle (Copland & Alders, 2004). 
However their behaviour makes them prone to or exposes 
them to the spread of ND and other similar diseases, as 
despite being from multiple households, chickens will often 
congregate when scavenging so in effect forming one large 
village flock of all-ages and with unknown genetics. This 
enhances the transmission of infectious agents which has major 
implications for vaccination strategies (Msoffe et al., 2010). 
ND epidemics can result in up to 100% morbidity and 100% 
mortality in unvaccinated flocks with disastrous socio-eco-
nomic consequences for both commercial and small poul-
try keepers (Alexander, 2000; Alexander & Senne, 2008; 
GALVmed-PANVAC-IIAM, 2009; Spradbrow, 2000) so poten-
tial losses due to ND make vaccination mandatory (Copland & 
Alders, 2004). 
Control of ND by vaccination is widely practised in com-
mercial poultry flocks. However the vaccines used in the 
commercial sector are less suited for use in the village chick-
ens of low–middle income countries (Aini et al., 1990; 
GALVmed-PANVAC-IIAM, 2009). Typically, commercial vac-
cines are produced in large dose vials, are often insufficiently 
thermotolerant so require a dependable cold-chain and gener-
ally are too expensive for use in village flocks. These issues 
led to the characterisation of thermotolerant ND virus vaccine 
strains that could be produced inexpensively in smaller 
batches by local laboratories for use in all-age backyard flocks 
(Campbell et al., 2019; Domingue et al., 2017; Spradbrow, 
1993/1994). An example of such a vaccine is the naturally 
attenuated, thermotolerant I
2
 ND virus, now commonly known 
as I-2, which has long been known to be a suitable vaccine for 
use in developing countries. This is due partly to its high titre 
yield in embryonated eggs, its lack of virulence, a low patho-
genicity coupled to a high immunogenicity which confers 
substantial protection, its thermotolerance (at least 12 weeks 
when stored at 22oC in 1% gelatin), its straightforward deliv-
ery routes including by eye drop, its contact spread between 
birds and its safety and efficacy in very young (8 day) African 
local ecotype chicks (ACIAR, 2005; Bensink & Spradbrow, 
1999; Copland & Alders, 2004; Dias et al., 2001; Domingue 
et al., 2017; Henning et al., 2009; Kattenbelt et al., 2006; Tu 
et al., 1998; Wambura et al., 2000; Wambura et al., 2006; Wambura 
et al., 2007). While the ND I-2 vaccine is thermotolerant, it 
eventually loses its potency if exposed to excessive sunlight 
or temperatures for long periods, i.e. it is not thermostable 
(Copland & Alders, 2004). This was partly addressed for ther-
motolerant ND vaccines in general by Domingue et al., 2017 
who demonstrated that a preparation of 10X field dose of Clone 
30 could offset viability loss due to high temperature (24 h, 
32.3°C) while retaining safety and efficacy.
I-2 Master Seed (MS) is maintained by the University of 
Queensland, Australia and owned by the Australian Centre for 
International Agricultural Research (ACIAR) who make it avail-
able at no cost to low-middle income countries wishing to 
establish local ND vaccine production. (Alders & Spradbrow, 
2001). ND I-2 vaccine use has also been allowed in these 
low-middle income countries because local registration require-
ments are relatively relaxed, but the vaccine has not been 
registered in those countries where registration requirements 
are more demanding.
The Global Alliance for Livestock Veterinary Medicines 
(GALVmed) is a not-for-profit organisation that helps develop 
and register veterinary medicines for livestock in those markets 
that are not attractive to the global commercial animal health 
industry. GALVmed has prioritised livestock diseases in low - 
middle income countries depending on perceived unmet need 
          Amendments from Version 1
Shahn P.R. Bisschop et al. Some of the reviewers acknowledged 
the importance or excellence of the study and its appropriate 
design. Also none of our interpretation of the regulatory 
demands and the results was found to be incorrect. No 
corrections of Figures and Tables were necessary. There were no 
updates required to the Author list. Here we state our response 
to the comments from the 3 reviewers. We have responded by 
making 14 amendments and rebuttals which are in this revised 
version and also we refer readers to our already submitted point-
by-point responses which include some rebuttals.
Throughout: in response to Prof Alders we have corrected 
“Newcastle Disease “to “Newcastle disease” so that it is in line 
with OIE standards.
Abstract: in response to Prof Alders the last sentence now reads 
as “From an international regulatory perspective, the study 
provides further definitive data demonstrating that Newcastle 
disease vaccine virus I-2 is safe for use.”
Introduction: “ Unfortunately the behaviour of village birds make 
them prone to disease spread” has been replaced with “However 
their behaviour makes them prone to or exposes them to the 
spread of ND and other similar diseases” in response to Prof 
Alders and Dr Msoffe.
“and with unknown genetics” has been deleted in response to  
Dr Msoffe’s comment.
We have deleted “Currently only one serotype of ND virus is” in 
response to Dr Morrow and “especially to help AU-PANVAC in its 
pro-poor aims” in response to Dr Msoffe.
We deleted “This has delayed or prevented registration in a 
number of low-middle income countries” and inserted “of an 
international regulatory standard” in response to Prof Alders and 
Dr Msoffe’s comments.
Methods: “SPF” has been inserted throughout as per Dr Morrow’s 
comment.
Discusssion: “Dr Spradbrow” has been changed to “Professor 
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irrespective of species and target diseases, and so has included 
ND in poultry for development funding.
Despite I-2’s long known suitability, there is a need to develop 
a globally acceptable I-2 registration dossieras agreed with 
the Bill and Melinda Gates Foundation. Indeed one of the 
obstacles to the wider use of the I-2 vaccine has been that no 
comprehensive dossier of an international regulatory standard 
has been compiled on the vaccine. Data confirming that the 
vaccine virus does not increase in virulence after serial passage 
through chickens is an essential component of such a dossier.
Therefore there was a universal requirement to re-investigate 
the naturally attenuated I-2 ND vaccine strain but under 
appropriate regulations to determine whether it would acquire 
virulence after five serial in vivo passages in SPF chickens. 
Accordingly, GALVmed sponsored a trial to good labora-
tory principles (GLP) (OECD, 1998) at the Veterinary Faculty 
of the University of Pretoria at Onderstepoort, South Africa. 
The study design incorporated the demands of the European 
Pharmacopoeia (Ph. Eur.), 2013; VICH GL 41, 2007 and 
the European Union Council Directive 81/852/EEC, 1981 
to meet the requirements of a large number of countries so 
that the vaccine might be widely accepted by international 
registration authorities.
Methods
I-2 Newcastle disease (ND) virus
Master seed (MS) was a gift from ACIAR (Australian 
Centre for International Agricultural Research). Preparation of 
MS and working seed (WS) was as described (ACIAR, 2005). 
Briefly MS was reconstituted, titrated, diluted and inoculated 
into embryonated eggs. After 4 days incubation the allantoic 
fluids were pooled and the WS harvest was titrated, adjusted to 
4.0 × 109 EID
50
 ml-1/ 8.4 × 1010 GC, genomic copies, ml-1 and 
stored at -70oC.
Study practice and design
Design complied with international regulatory requirements 
(Ph. Eur. v9.0 04/2013:0450, 2013; VICH GL 41, 2007; EU 
Council Directive 81/852/EEC, 1981) to ensure global accept-
ance. Study practice including data collection and storage was to 
Good Laboratory Practice (GLP) -like principles (OECD, 1998). 
All Study practice and design activities were performed under 
the umbrella of the GALVmed Quality Control system (VICH 
GL 41, 2007 standard). The study flow designs are shown in 
Figure 1a and 1b.
Briefly, the prescribed test for “increase in virulence” (European 
Pharmacopeia, Ph. Eur. v9.0 04/2013:0450, 2013) requires 
that native I-2 ND vaccine virus be administered to birds at 
“the least attenuated passage level present between the 
MS lot and a batch of vaccine”. Since only one vial of ND I-2 
MS was available, the least attenuated passage level was 
confirmed as Working Seed (WS; Ph. Eur. Helpdesk, personal 
communication).
The test for increased virulence, i.e. acquisition of virulence in 
the case of the naturally attenuated I-2, starts with the 5 times 
in vivo passage with at least 5 chicks per passage, of I-2 WS 
(i.e. native or non-passaged) to produce 5XP WS (i.e. 5X 
passaged WS).
The prescribed test then continues as the detection of any viru-
lence changes in ICPI (Intracerebral pathogenicity index), F
o
 
amino acid sequence and Safety assessments (see below and 
Figures 1a and 1b).
Five-times in vivo passage
Ph. Eur. v9.0 04/2013:0450, 2013 requires the administration 
by the intra-ocular (IO) route, of a quantity of I-2 virus in 
homogenates containing both brain and tracheal tissues, that 
will allow recovery of I-2 virus through the 5 passages.
There were two passage series and each used seven SPF 
1-day-old chicks per passage. In both series, to attempt the 
required I-2 recovery, the initial IO challenge, i.e. the challenge 
into the first passage birds, was 2.0 × 108 EID
50
/ 4.2 × 109 GC 
via 2 x 25 µl drops of native I-2 WS at 4 × 109 EID
50
 ml-1/ 8.4 
× 1010 GC ml-1. Next, for both series, four sequential IO chal-
lenges i.e. numbers 2 to 5 (2 x 25µl eye drops of pooled organ 
homogenate from the previous passage) and passages followed. 
Caecal tonsils were also collected in both series and inves-
tigated for viral titres, as although not demanded by the 
Ph. Eur. v9.0 04/2013:0450, 2013, this was normal procedure 
at the study site; N.B. caecal tonsils were never incorporated 
into any homogenates.
Critically, the two series differed in their homogenate 
compositions. The first passage series was for “range-finding” 
and used an initial IO challenge homogenate made up of 50% 
brain: 50% tracheal tissue. During each passage, birds were 
observed twice daily for 4 days, subsequently euthanised 
(cervical dislocation) and a pooled suspension of homogenised 
brain and tracheal tissue was prepared for the next passage. 
The presence of I-2 virus in the pooled suspension of homog-
enised brain and tracheal tissue from each bird in each passage 
was detected by egg passage and subsequent EID
50
 in HA 
and by real-time reverse transcription-polymerase chain reac-
tion (rRT-PCR) (see below). Unfortunately, this first passage 
series was incomplete as I-2 virus could not be detected after 
the fourth passage and throughout I-2 virus yields from brain 
tissue were very low or negative (see Results).
In accordance with the Ph. Eur. v9.0 04/2013:0450, 2013 and 
implementing advice from the Ph. Eur. Helpdesk, the second 
passage series was performed. An “augmented” homogenate 
consisting of 10% brain: 90% tracheal tissue to minimise the 
dilution effect of the brain material, was used as the challenge 
inoculum for passages 2 to 5. This approach was successful 
in that I-2 was isolated to the end of the fifth passage, albeit in 
very low titres. Although these were below the minimum chal-
lenge level of >2.0 × 108 EID
50 
ml-1 (i.e. 50 µl containing107 
EID
50
) specified by the Ph. Eur. v9.0 04/2013:0450, 2013 for 
the challenges for the subsequent ICPI and Safety tests, an 
exploratory approach was taken and the five times passaged 
I-2 was assessed against native WS I-2 in the ICPI, amino 
acid sequencing of the F
0
 cleavage site and Safety tests as 
described below.
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A.     ICPI: a daily scoring of signs for 8 days after intracerebral 
(IC) administration (0 = normal, 1 = clinical signs of dis-
ease, 2 = dead). For a virus challenge of not less than 108 
EID
50
 or for a virus challenge less than 108 EID
50
 but not 
less than 107 EID
50
, a virus would comply with the test 
if the ICPI induced was not greater than 0.5 or 0.4, 
respectively.
B.     Determination of the encoded amino acids at the I-2 F
0
 
cleavage site that imparts pathogenicity in ND viruses.
C.     Safety, an absence of clinical signs after ocular challenge, 
IO, the recommended vaccination route for I-2.
Bird numbers
To allow for mortality and to ensure that no treatment group 
included fewer birds than required in the Ph. Eur. mono-
graph above, the treatment group sizes were increased slightly 
above monograph requirements per group:
  Passage - 7 birds per passage for the first four 
passages and 10 birds for the fifth passage
  ICPI - 12 birds
  Safety - 22 birds
Groups of 6 birds each were present as negative controls for 
each test that included virus passages and safety tests on the 
WS and 5XP WS. Further groups of 6 chicks served as controls 
for the ICPI techniques.
Location
The study was conducted at the National Department of 
Agriculture-approved BSL3 laboratory isolation unit at the 
University of Pretoria, South Africa.
Ethics
Approval for the study was obtained in advance from the 
University of Pretoria Animal Use and Care Committee as well 
as the Research Committee of the Veterinary Faculty. Approval 
for the study was also obtained in advance from the National 
Department of Agriculture. These approvals and the GALVmed 
Quality Control System ensured that the study followed the 
principles of the Animal Research: Reporting of In Vivo 
Experiments (the ARRIVE full set 2.0) guidelines (Kilkenny 
et al., 2010). Any trial amendments were also approved by 
the above committees of the University of Pretoria.
Chickens
Mixed sex, specific pathogen free (SPF) Leghorn chickens were 
obtained either as eggs on the point of hatching or as day-old 
Figure 1. Flow design for (a) second series 5 times in vivo passaging of I-2; (b) ICPI, Fo sequencing and Safety tests of I-2.
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chicks (1 day; >24 h and <40 h; Deltamune (Pty) Ltd, SA). 
Birds (n = 290 in total) were placed immediately after hatching 
into approved BSL3 isolation cabinets (12 per cabinet; different 
treatment groups were allocated to separate isolation cabinets; 
Horsefall isolation units, SA) and remained housed within the 
BSL3 unit until euthanasia.
Inclusion/exclusion/withdrawal criteria for study 
chickens
Inclusion criteria
•  Day-old chicks (chickens) hatched from SPF eggs.
•  Chicks were clinically normal and in good health.
Exclusion criteria
•  Unhealthy chicks
•  In the event that more healthy chicks hatched than 
were required for the study, the study director excluded 
the smallest birds from the study.
Withdrawal criteria
•  Any abnormal signs considered to compromise the 
welfare of the chicken.
•  Any chicken requiring concurrent medication that 
could compromise its suitability for the study.
Randomisation and bias reduction. Randomisation plans 
were prepared by an independent biometrician. Chicks were 
individually identified using food colouring and/or coloured 
leg bands, so they could be assigned numbers and randomly 
allocated to treatment groups. Chicks were randomised to 
treatment and randomised between isolation cabinets. For 
some passages, no randomisation was performed as each treat-
ment group was placed sequentially and on different days. For 
all five passages, chicks in each isolator were individually 
marked using coloured leg bands. This was solely for the 
purpose of monitoring, so that investigators were able to deter-
mine if an individual chick had been in protracted recumbency 
or had consistently exhibited particular clinical signs. Post- 
challenge observation and clinical scoring was conducted by two 
observers and by different observers throughout the different 
phases of the study in order to reduce observer bias.
Five-time in vivo passage (5XP) of I-2 WS and 
comparisons of 5XP I-2 with native I-2 WS
Tissue homogenisation (for preparation of passage chal-
lenges). Post-mortem, organs were placed into a solution at a 
dilution of 1 part tissue: 4 parts PBS (phosphate buffered saline, 
pH7.4) containing antibiotics (penicillin 1,000 units ml-1 and 
streptomycin 10,000 µg ml-1) and an anti-mycotic (amphotericin 
B 25 µg ml-1) and blended.
I-2 quantification. All challenges for the in vivo passaging, 
ICPI and safety tests were quantified at time of use in the HA 
and rRT-PCR assays below as were all test yields.
Quantification by haemagglutination inhibition (HAI) test. 
After each in vivo passage in chickens, organ homogenate 
was inoculated into the allantoic cavity of a series of 11-day 
embryonated SPF eggs and the EID
50
 calculated according to 
the method of Reed & Muench (1938) using the macroscopic 
haemagglutination technique (Anon, 1989).
Quantification by rRT-PCR. This was implemented for I-2 
virus quantification because post-passage yields were very low 
making quantification by the gold standard of HA unreliable 
or impossible. The authors acknowledge that the Ph. Eur. v9.0 
04/2013:0450, 2013 monograph does not consider genomic 
copy units.
RNA extraction. I-2 RNA was extracted from homogenised 
tissue samples or allantoic fluids using Tri-Reagent (TR 118, 
Molecular Research Center Inc.; Cincinnati, OH, USA) 
followed by further purification of RNA using the Qiagen 
RNeasy® MinElute™ Cleanup Kit (Cat No 74204; Qiagen, The 
Scientific Group, Gauteng, South Africa) and elution of RNA 
in 15 µl of RNase-free water (Cat No 129112; Qiagen). Three 
µl of RNA was used in RT-PCR reactions with final volumes of 
10 µl.
Primers and probes. The primers NDF and NDR were used 
in combination with probe “NDpro2” as described in Fuller 
et al., 2010. Primer and probe sequences were confirmed prior 
to testing and the probe sequence was confirmed as identical 
to the published sequence of ND I-2 virus. Primers and Probes 
were synthesised by TibMolbiol, Berlin, Germany. Primers 
were used at a final concentration of 200 µmolar and the probe 
at a final concentration of 100 µmolar in each reaction.
Assay details. The rRT-PCR of Fuller et al., 2010 was adapted 
(Jang et al., 2011) to a Roche LightCycler® 480 and dedi-
cated reagents (Hoffmann-La Roche Ltd, South Africa). 
After optimisation, the LightCycler® RNA Amplification 
Kit HybProbe (Cat No 12015145001; Hoffmann La Roche) with 
a final MgCl
2
 concentration of 7 mM was used. A total of 3 µl 
purified RNA was used to give a final 10 µl reaction volume.
Cycling parameters were as follows: 55°C for 10 minutes – 
(reverse transcription), 95°C for 1 minute – (initial denaturation); 
followed by 40 cycles of amplification followed by 95°C for 
5 seconds (denaturation), 55°C for 5 seconds (primer binding), 
60°C for 20 seconds (hydrolysis of probe and acquisition of 
fluorescence); cooling to 40°C for 10 seconds.
In each run, in order to quantify virus, at least three standard 
solutions containing known amounts of Newcastle disease virus 
I-2 GC were also analysed – the standards were prepared after 
purification of ND I-2 on a sucrose gradient, extraction of 
RNA from purified virus, and quantification of RNA (8.1 ng of 
NDV RNA represents 109 NDV GC. From a stock containing 
109 GC µl-1, 10-fold serial dilutions were made from 109 
to 1.0 GC µl-1. Quantification of RNA copies per ml of 
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homogenised sample were calculated by multiplication of 
the genomic copies per PCR reaction by the dilution factor 
used during RNA purification.
Assessment of possible increase in virulence
ICPI test. Each bird in the WS group (n=12) was given an 
intracerebral (IC) challenge of 50 µl from pooled allantoic stock 
containing 4 × 109 EID
50
 ml-1/ 8.4 × 1010 GC ml-1 of I-2 ND 
virus (i.e. 2 × 108 EID
50
 / 4.2 × 109 GC total).
Those birds (n=12) challenged with 5x passaged WS received 
50 µl IC of a homogenate composed of 90% tracheal tissue 
containing 5.1 × 106 EID
50
 ml-1/ 4.1 × 107 GC ml-1 of I-2 and 
10% brain tissue with no I-2 detected in both rRT-PCR and 
HAI. The total I-2 challenge was 2.6 × 105 EID
50
/ 2.1 × 106 
GC which was below the minimum challenge level (Ph. Eur. 
v9.0 04/2013:0450, 2013) for the ICPI tests. 
Two control groups (n=6 each), one for each test group 
above, received a 50 µl IC challenge of PBS intracerebrally. 
Test and control birds were observed (clinical administration 
post vaccine administration, CEPVA) at 1 h and 4 h post- 
treatment and then at least twice daily for 8 days.
An ICPI was calculated for the chickens according to the Ph. 
Eur. v9.0 04/2013:0450, 2013. The ICPI is the mean of the 
scores per bird per CEPVA, performed twice a day, over an 
8-day period: 0 = clinically normal; 1 = clinical signs of 
disease; 2 = dead. I-2 would comply with the test if the ICPI 
induced was not greater than 0.5 or 0.4 respectively.
F
o
 amino acid sequencing. Pooled, homogenised 10% brain: 
90% trachea samples were analysed. The encoded amino acids 
at the F
0
 cleavage site in RNA preparations from I-2 WS and 
5 XP ND I-2 were determined via the RNA sequencing service 
of the Molecular Epidemiological and Diagnostic Programme, 
Agricultural Research Council - Onderstepoort Veterinary Insti-
tute, Pretoria, South Africa. Sequencing reactions were prepared 
using a BigDye Terminator v3.1 sequencing kit (Applied Biosys-
tems, USA) and a 3500/3500xL Genetic Analyzer (Applied Bio-
systems). Multiple sequence alignments were performed using 
the BioEdit v 7.1 sequence alignment (Hall, 1999). The derived 
amino acid sequences were obtained using the ExPASytranslation 
tool (v 2003; Gasteiger et al., 2003).
Safety test. Each bird in the native WS group (n=22) received 
50 µl of 4 × 109 EID
50
 ml-1/ 8.4 × 1010 GC ml-1 of I-2 adminis-
tered IO as two 25 µl drops (2 × 108 EID
50
 / 4.2 × 109 GC total 
challenge).
Each bird in the 5XP WS group (n=22) received 50 µl of a 
homogenate composed of 10% brain tissue (I-2 not detected in 
rRT-PCR and HAI): 90% tracheal tissue (containing 5.1 × 106 
EID
50
 ml-1/ 4.1 × 107 GC ml-1 I-2) and administered IO as 
two 25 µl drops (2.6 × 105 EID
50
/ 2.1 × 106 GC total chal-
lenge). Again this was below the minimum challenge level 
specified by the Ph. Eur. v9.0 04/2013:0450, 2013.
Negative control birds (n=6) for each safety test received 
PBS pH 7.4 in two 25 µl eye drops. All birds were observed at 
1h and 4h post-treatment and then at least twice daily for 
21 days.
Control birds. All controls were examined for I-2 virus as above 
to detect possible accidental cross-inoculation except that for 
the rRT-PCR, choanal cleft swabs were pooled and analysed. 




Negative, untreated and placebo control groups were present 
in the same study rooms during the I-2 in vivo passages, the 
safety tests and the ICPI tests. No abnormal clinical signs were 
observed in any negative control chickens. ND I-2 was 
never detected in any tissue samples. Again I-2 was never 
isolated from “sentinel” chickens indicating that biosecurity 
was satisfactory throughout the study.
In vivo passages. Only one bird was withdrawn from the study. 
This bird subsequently died from a cloacal prolapse which 
was judged not to be linked to the challenge. No birds died in 
any of the in vivo passage groups, or in the control groups.
No signs of clinical disease in chickens were observed as 
a result of challenge with ND I-2 WS, whether native or 
five-times-passaged material (organ homogenate), in any of 
the passages. The first attempt at passaging was not success-
ful in that virus could not be detected after the fourth passage 
but it was noted that viral loads in the tracheal tissues were 
3–5 times greater than in the brain tissues (data not shown).
In the second series of passages, an augmented homogenate 
consisting of 10% brain: 90% tracheal tissue was used for the 
IO challenges for each group and this proved more success-
ful as 5XP I-2 WS was obtained. The HA and rRT-PCR analy-
ses of the tissues recovered from each passage are shown in 
Table 1. Significantly, I-2 was not detected in brain tissues 
through all passages and overall, virus titres in all harvested 
tissues were below the minimum challenge level of >2.0 × 
108 EID
50 
ml-1 (i.e. 107 EID
50
 in 50 µl per chick) specified in the 
Ph. Eur. v9.0 04/2013:0450, 2013 for the challenge for the 
ICPI and Safety tests: the highest tracheal yields for I-2 were 
5.1 × 106 EID
50
 ml-1/ 4.1 × 107 GC ml-1 (passage 5) while those 
for caecal tonsils were 1.8 × 107 EID
50
 ml-1/ 6.0 × 108 GC ml-1 
(passage 2). Despite the low HA titres, it was decided that, given 
the exploratory nature of this work, to continue with the ICPI 
and Safety tests with a challenge homogenate composed of 
both brain and tracheal tissue to ensure compliance but with 
the former at only at 10%, to minimise the dilution effect of 
the brain material.
Comparative tests
ICPI. Clinical observations were twice daily. For WS, 4 
of 12 birds (33.3%) showed clinical signs as a result of 
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ill-health and an unwillingness to drink associated with the 
effects of the ND challenge as observed post-mortem. Two other 
birds were also seriously ill by the end of the study. There were 
two deaths due to dehydration shortly before the end of the 
study in this group - one bird was sick on day 7 and was found 
dead on the morning of day 8. One bird was noted as sick on the 
morning of day 8 and died on the final morning, day 9. Addi-
tionally, one bird was recorded as being sick on days 8 and 9 
while a final bird was found sick on the morning of day 9. The 
ICPI value for the native ND I-2 WS was 0.104 for 96 possible 
observations i.e. 10/ 96 = 0.104. The native WS I-2 there-
fore complied with the test with an ICPI not greater than the 
cut out value of 0.4. 
For 5XP WS, two of 12 birds (16.7%) showed depres-
sion and died shortly before the end of the study on day 8 of 
observation. On post-mortem examination, both birds showed 
signs of dehydration. Two (16.7%) other birds were also seri-
ously ill by the end of the study and three birds showed 
decreased activity when compared with birds in the ICPI con-
trol group. The ICPI value for the 5XP I-2 WS was 0.073 for 
96 possible observations i.e. 7/ 96 = 0.073. The 5XP I-2 virus 
seemingly complied with the test as its ICPI was less than 
0.4 but this is qualified as the challenge used was less than 
that required by the Ph. Eur. v9.0 04/2013:0450, 2013.
For both test groups, the negative control chickens showed 
no abnormal clinical signs related to the IC PBS challenge.
Amino acid sequencing. Samples from WS and 5XP WS 
were identified by BLAST analysis of the cDNA sequence as 
ND I-2 vaccine strains. The translated amino acid sequences at 
the fusion protein cleavage site (F
O
) for both WS and 5XP WS 
were identical, namely 112R-K-Q-G-R-↓-L-I-G119 and further, 
were consistent with those of avirulent ND viruses,
Safety. Generally no clinical signs of abnormal health were seen 
in chickens from both native WS I-2 and 5XP WS I-2, except 
for two chickens in the 5XP WS group: one bird developed a 
vent prolapse and was consequently excluded from the study, 
while another bird showed neurological signs and lateral recum-
bency before death. The post-mortem for this bird was incon-
clusive but dehydration signs were observed. Both native 
WS I-2 and 5XP WS 1-2 (given the low challenge level) had 
complied with the test as the cut out of < 10% of birds dying 
was not exceeded. The control birds never showed abnormal 
clinical signs.
Discussion
The Ph. Eur. v9.0 04/2013:0450, 2013 requires that all 
tissue homogenate challenges for in vivo passage must contain 
brain tissue. The first five times passage series used a 50% 
brain: 50% trachea ratio, meaning that I-2 in tracheal tissue 
was diluted by brain tissue (I-2 not detected) rendering the 
first series invalid. The second passage series used a homoge-
nate ratio of 10% brain: 90% trachea which was more effective 
but again I-2 was not detected in brain tissue. The titres 
in tracheal tissues were highest after the fifth passage at 
5.1 × 106 EID
50
 ml-1 but still below the minimum challenge level 
of >2.0 × 108 EID
50 
ml-1 required for the ICPI and Safety tests 
(Ph. Eur. v9.0 04/2013:0450, 2013). This seemed to indicate 
that the birds were holding the infection at low levels throughout 
the passaging, which probably reflected the inherently low 
level of pathogenicity for ND I-2 (Dr Peter Spradbrow, per-
sonal communication). Significantly, no evidence was obtained 
of “conditioning” or habituation of the I-2 virus that would have 
resulted in increasing yields through the passages, for both tra-
cheal and caecal tonsils tissues. The Ph. Eur. v9.0 04/2013:0450, 
2013 notes that if virus (i.e. I-2) is not recovered after the 
two passage series, then it is compliant with the test. Despite 
the low 5XP WS I-2 titres, it was decided for exploratory 
reasons to use the available material and continue with the 
ICPI, sequencing and safety tests.
In the ICPI tests, some birds died in both WS and 5XP WS 
groups subsequent to IC. This occurred towards the end of the 
trial period. The mortalities were in a small number of birds 
such that the ICPI values calculated were well within accept-
able limits (Ph. Eur. v9.0 04/2013:0450, 2013) and low when 
compared to results for control birds. 5XP WS did not acquire 
virulence as partial genomic sequencing showed no changes 
in the structure of the fusion protein site F
o
. In the safety tests, 
one bird in the 5XP WS group died despite the low titre chal-
lenge, from unknown causes that could not be distinguished 
from the possible effects of ocular challenge with ND I-2 virus. 
According to the Ph. Eur. v9.0 04/2013:0450, 2013, this 
single death rendered the safety test inconclusive. However, 
the five-times-passage data, the ICPI and rRT-PCR sequencing 
data and the apparent lack of conditioning contrasted strongly 
with the Safety results. The sequencing data for WS and 5XP 
WS confirmed no change within the pathogenicity locus. How-
ever other sequences were not examined so it is possible that 
other pathogenicity sequences in 5XP WS were modified 
(upregulated) by the in vivo passages to give this deleterious 
effect (the I-2 genome with Genbank accession number 
AY935499).
Obtaining sufficient 5XP WS was another difficulty as Ph. Eur. 
v9.0 04/2013:0450, 2013 allows flexibility over the number of 
birds used in the ICPI (>10 birds) and Safety tests (>20 birds). 
However, for five-times passaging, the monograph states 
that 5 birds (only) are to be used for each passage; in fact, 7 
birds were used for each passage in this study to improve the 
chance of I-2 re-isolation between passages. Critically for us, 
the one big technical problem with the Ph. Eur. monograph 
was due to the number of birds in the fifth in vivo passage that 
limited the amount of virus available for the ICPI and Safety 
tests. Amplification of the I-2 titre in the 5XP WS homoge-
nates by using embryonated eggs for a preliminary amplifica-
tion phase before carrying out the ICPI and Safety tests was 
forbidden (Ph. Eur. Helpdesk, personal communication). To 
obtain the quantity of virus required, a minimum of 24 chick-
ens would have been required for the fifth passage and to 
obtain sufficient material for this final challenge, the number of 
birds in the fourth passage would also have had to be increased 
substantially. This would represent a major deviation from 
the Ph. Eur. v9.0 04/2013:0450, 2013 that would not be 
permitted by the Ethics Committee of the University of Pre-
toria. The option of concentrating the challenge material was 
considered but this was not practical given the small quantity 
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(≤5 ml) of tracheal tissue available from the birds in the chal-
lenge groups. Increasing the concentration of the challenge 
homogenate from a concentration of 5.1 × 106 EID
50
 ml-1 to 
2.0 × 108 EID
50
 ml-1 would require the material to be concentrated 
approximately 40 times. It was noted that the caecal tonsils 
gave a significant I-2 yield and perhaps this might be of use in 
increasing total yields of avirulent viruses. Hopefully the Ph. 
Eur. monograph may be reviewed and adapted to account for the 
above findings (Ph. Eur. Helpdesk, personal communication) 
and so ease the rigours of international compliance for aviru-
lent vaccine viruses like I-2 which are of strategic importance 
in pro-poor vaccination programmes. The Ph. Eur. also may 
need to consider both HAI and genomic quantification of viruses. 
Our suggestion for a review of the Ph. Eur. monograph reflects 
increasing knowledge and is in keeping with e.g. the sugges-
tion to include assessments of viral shedding in vaccine safety 
and efficacy regulatory documents (Cardenas-Garcia et al., 
2015).
I-2 was difficult to passage repeatedly in vivo and it induced 
very low ICPI values, both before and after in vivo passage. 
Sequencing data for the F
o
 site confirmed that 5XP I-2 WS had 
not acquired virulence here. I-2 caused no signs of overt clini-
cal disease in a Safety eye drop challenge and overall there was 
no evidence of conditioning of I-2. This study confirms that 
Newcastle disease vaccine virus strain I-2 is safe for use in 
chickens but further validation work particularly examining the 
reproducibility of the passage data is needed.
Data availability
Underlying data
Open Science Framework: Acquisition_Reversion to Virulence 
of I-2 NDV, https://doi.org/10.17605/OSF.IO/6Z8JM (Domingue, 
2021).
This project, among other information, contains the following 
underlying data:
• Quality training
•  Animal husbandry and management including health 
observations and post-mortem analyses
• Blinding and bias reduction methods
•  Preparation of brain: tracheal tissue challenge 
homogenates
•  Five times in vivo passaging methods and virus 
yields (rRT-PCR and HA analyses)
•  Observational scores for the safety tests for each animal
•  Observational scores for ICPI tests for each animal
•  F
0
 amino-acid sequence determinations
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
The following data files are temporarily unavailable due to the 
site where these data are kept being currently under lockdown 
(at time of publication) owning to the COVID-19 pandemic. 
Once restrictions are lifted, the authors are committed to upload-
ing the data and versioning the article so that all underlying are 
available to readers. In the meantime, for any clarifica-
tions about the data or analysis, readers should contact the 
GALVmed CEO or Chief Scientific Officer via the GALVmed 
website (https://www.galvmed.org/)
-  Viral titres for each animal/tissue
-  Raw Ct values obtained from rRT-PCR for each run
-  Raw results of the hemagglutinin inhibition test for 
each animal/tissue
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Keywords: change the upper case 'D' for Newcastle disease to a lower case 'd'; 
 
Introduction: the phrase "because local registration requirements are relatively relaxed" remains 
problematic. This wording suggests a value judgement on the part of the authors. It would be 
ideal if the authors could reflect how risk assessments differ across countries and regions. While 
the EU regulations may be appropriate for EU countries, the risks that the EU deals with are in 
many cases substantially different to those faced by low-income countries. I agree with the 
observation by one of the co-reviewers that the OIE standards may be more appropriate given the 
varied circumstances under which ND needs to be controlled. The importance of national level risk 
assessments is covered in Young et al. (20121). 
 
Discussion: Peter Spradbrow's title remains written as 'Dr'. Please change this to 'Professor'. 
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The authors may want to modify the statement: "...the behavior of village birds is suited to 
the disease spread..." to more like: the behavior of the village birds make them prone or 
expose them to the spread of ND and other similar diseases. 
 
1. 
The phrase "...of unknown genetic" is superfluous because it is not yet established if chicken 
genetics play any significant role the epidemiology of ND. 
 
2. 
I hesitate to agree with the authors that I-2 ND vaccine is registered in some countries 
because of less stringent registration procedures. I think it is more because I-2 is a vaccine 
that responded to a real need named lack of cold chain in most lower and middle income 
countries! Possibly most countries that have not registered the vaccine particularly the high 
income ones have not done so due to lack of a pressing need since the existing 
thermolabile vaccine appears to be sufficient. 
 
3. 
For a study that is centered on assessing the phenomenon of vaccines acquiring virulence 
after in-vivo passages, I expected this topic to be covered in the introduction and discussion 
sections of the manuscript including relevant citations. Absence of this information makes it 




The authors assert that development of a global I-2 dossier will help AU-PANVAC in its pro-
poor aims; however, it is not explained anywhere in the text what challenges AU-PANVAC is 




From the methodology it appears that the study design was to ensure EU acceptance rather 
than what the authors are describing as global acceptance. One would expect that a global 




It appears that the control birds were kept within the same premises with the test birds. 
However, it appears that no I-2 ND virus was detected in the control birds. This information 
seems to contradict with the established evidence that I-2 is highly transmissible within 
flocks. Any clarifications? 
 
○
The use of the phrase "ND challenges" when describing the ICPI results is inappropriate as 
it may lead to confusion to the reader whether virulent strains were used. I recommend that 
the authors maintain I-2 challenge throughout the text. 
○
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
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Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Poultry health and production
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 10 Jun 2021
Gil Domingue, GALVmed, Pentlands Science Park, Midlothian, Scotland, UK 
1. The authors may want to modify the statement: "...the behaviour of village birds is suited 
to the disease spread..." to more like: the behavior of the village birds make them prone or 
expose them to the spread of ND and other similar diseases. 
We agree. 
 
2. The phrase "...of unknown genetic" is superfluous because it is not yet established if 
chicken genetics play any significant role the epidemiology of ND.  
What we meant here was that there is a genetic influence upon the comparative resistance to 
infection; this can be manifested in bird – bird variation. We will delete this. 
 
3. I hesitate to agree with the authors that I-2 ND vaccine is registered in some countries 
because of less stringent registration procedures, etc. 
We will delete this text. 
 
4. For a study that is centered on assessing the phenomenon of vaccines acquiring virulence 
after in-vivo passages, etc 
We think that the last two paragraphs of the Introduction explained why the study was 
performed. We are restricted by space considerations so do not think we need to expand further. 
 
5. The authors assert that development of a global I-2 dossier will help AU-PANVAC in its 
pro-poor aims, etc.  
“Boosting” the I-2 registration dossier for AU-PANVAC was just for general purposes which are 
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now superseeded. We will delete the reference to AU-Panvac. 
 
6. From the methodology it appears that the study design was to ensure EU acceptance, etc. 
We note this comment but here we were guided by the GALVmed Technical Subcommittee 
(international experts) to work to OECD GLP and Ph. Eur. as international standards. There was a 
Galvmed policy decision to be guided more by international regulatory authorities, e.g. Ph. Eur. 
(tough) than OIE.  
 
7. The use of the phrase "ND challenges" , etc. 
We have noted this. 
 
Additional reply: 
1. "It appears that the control birds were kept within the same premises with the test birds. 
etc" 
It is because I-2 virus is highly transmissible that we worked within a BSL3 standard laboratory 
isolation unit with separate isolation cabinets and a high efficiency ventilation system. Unique 
BSL3 Isolation Cabinets were used for within-test Test and Control birds. Sentinel birds were 
placed throughout the working areas.    
Competing Interests: Not applicable
Reviewer Report 13 May 2021
https://doi.org/10.21956/gatesopenres.14430.r30651
© 2021 Morrow C. This is an open access peer review report distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Christopher J. Morrow   
1 The University of Melbourne, Melbourne, Vic, Australia 
2 Bioproperties, Melbourne, Vic, Australia 
This paper is a summary of an EU standard study (GLP/GCP) aimed to support registration of I-2 
from the University of Queensland Master Seed. It is not a scientific study but a registration study. 
VICH 41 (and the derived EP and other monographs) are recognised as flawed with no positive 
control group to assure that an increase in virulence would be detected if it occurred during the 5 
passages. (This is probably in the mistaken belief that we are reducing the number of animals 
used in experiments - a laudable welfare aim but if the vaccine is registered on such a flaw many 
more animals could suffer). Such a positive control group would assure that if the agent being 
tested had increased in virulence that such an increase would be detected by the challenge model 
being used.  
 
I agree with the authors that the Ph. Eur. v9.0 04/2013:0450 is unsuitable for testing viscerotrophic 
NDV vaccines with its insistence that only trachael- and brain derived-inocula is used for 
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transmission. I am not sure that the EU helpdesk advice that in vitro amplification between 
passaging is completely excluded is correct. Usually if direct passage without in vitro progation 
has been attempted and is not successful twice (as described in this paper) applicants would make 
a case for using in vitro passage amplification and I would have thought most (valid) ICPI testing 
would have used allantoic fluid and it may not have been validated for the final passage material 
being assessed and therefore brain and tracheal homogenate would need extra controls in the 
ICPI test. At least in the final passage before the safety testing in vitro passage may be needed). 
 
The statement that "Currently only one serotype of ND virus is recognised" is tautological as 
haemagglutinating viral isolates are identified as NDV by their serological characterization by sera 
raised against a NDV type strain raised antibody.   
 
The stated aim of the project to generate local manufacture of inexpensive vaccine is now an 
anachronism with regulation creep imposing first world quality standards on vaccines in nearly all 
countries. The need for SPF eggs for vaccine manufacture  and GMP standards are nearly 
universal and an expense. The need to protect chickens from viral and other contaminates is hard 
to argue against (having suffered through REV, EDS-76, ALV, CAV over the years). The materials 
and methods do not state whether SPF eggs were used for the initial propagation of the material 
studied. 
 
It is not clear what SPF definition has been used for this work.
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: Bioproperties manufactures V4 NDV Vaccine. I confirm that this potential 
conflict of interest did not affect my ability to write an objective and unbiased review of the article.
Reviewer Expertise: Avian mycoplasma.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
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significant reservations, as outlined above.
Author Response 10 Jun 2021
Gil Domingue, GALVmed, Pentlands Science Park, Midlothian, Scotland, UK 
1. This paper is a summary of an EU standard study (GLP/GCP) aimed to support registration 
of I-2 from the University of Queensland Master Seed. It is not a scientific study but a 
registration study. VICH 41 (and the derived EP and other monographs) are recognised as 
flawed with no positive control group to assure that an increase in virulence would be 
detected if it occurred during the 5 passages. ...etc. 
 
We agree this to be the case but the intention was to follow the Ph. Eur. as an accepted 
international standard for regulatory purposes. An early Galvmed policy decision handed down 
by GALVmed's independent Technical Subcommittee (international experts) was to be guided 
more by international regulatory authorities than by OIE.. Therefore the Ph. Eur. (more 
demanding) became the international standard for us. As a result, the study design is acceptable 
from a regulatory point of view but lacks positive controls. However we never detected any 
"conditioning" that enhanced the virulence of I-2 ND virus. 
 
2. I agree with the authors that the Ph. Eur. v9.0 04/2013:0450 is unsuitable for testing 
viscerotrophic NDV vaccines with its insistence that only trachael- and brain derived-inocula 
is used for transmission. I am not sure that the EU helpdesk advice that in vitro 
amplification between passaging is completely excluded is correct etc. 
 
The Ph. Eur. Helpdesk confirmed in writing (in our confidential records) that using embryonated 
SPF eggs for a preliminary amplification phase before carrying out the ICPI and safety tests was 
forbidden; this after being informed that we needed to do a second series. There was no reason 
to proceed to a third series when we might have got permission to use in vitro passage 
amplification. 
 
3. The statement that "Currently only one serotype of ND virus is recognised" is tautological 
etc. 
 
We accept this and will delete the statement. 
 
4. The materials and methods do not state whether SPF eggs were used for the initial 
propagation of the material studied. It is not clear what SPF definition has been used for 
this work etc. 
 
SPF eggs were used throughout including for MS inoculation. We will revise the text to make this 
clearer. 
Our Specific Pathogen Free (SPF) Eggs were fertile chicken eggs produced from known SPF parent 
flocks established and maintained as per the recommendations of a committee appointed in 
1974 by the International Association of Biological Standardization (IABS) Geneva, chaired by Dr. 
R. Luginbhul. We do not feel our manuscript would gain from including this detail.  
Competing Interests: No competing interests were disclosed.
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Reviewer Report 04 May 2021
https://doi.org/10.21956/gatesopenres.14430.r30601
© 2021 Alders R. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Robyn G. Alders   
1 Global Health Programme, Chatham House, Royal Institute of International Affairs, London, UK 
2 Australian National University, Canberra, Australia 
3 Kyeema Foundation, Brisbane, Australia 
This study builds on previous in vitro and in vivo research by investigating whether the naturally 
attenuated, thermotolerant Newcastle disease vaccine virus I-2 could acquire virulence after five in 
vivo passages through SPF chickens. This is an important contribution to the literature. 
 
The article can be improved by the addition of key information and some re-phasing of statements 





Please correct the writing of Newcastle disease so that it is in line with OIE standards, i.e. 




Last sentence: please reword to indicate that this current study provides additional and 
definitive evidence that the I-2 ND strain is safe to use. Significant studies have been done 
previously into the safety of the I-2 ND strain, including multiple passages in embryonating 
eggs. It has found not to cause clinical signs at 100x the standard dose in chickens. It causes 




Please revise the statement “Unfortunately the behaviour of village birds is suited to disease 
spread” as this is incomplete and somewhat misleading. In terms of disease transmission, 
reproductive rates of pathogens are higher in intensively raised poultry and the frequent 
movement of birds and fomites along poultry value chains facilitates disease spread. That 
the village should be considered the epidemiological unit for village poultry was clearly 
understood during the HPAI H5N1 pandemic. It was the intensive commercial poultry 
industry that disproportionately facilitated the wide spread of the H5N1 subtype as 
reported in multiple papers. 
 
○
Please revise the statement “ND I-2 vaccine use has also been allowed in these low-middle 
income countries because local registration requirements are relatively relaxed, but the 
vaccine has not been registered in those countries where registration requirements are 
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first vaccine to go through a registration process and so contributed to building regulatory 
capacity in these countries. Information dossiers were prepared in each case. 
 
Please revise the statement “Indeed one of the obstacles to the wider use of the I-2 vaccine 
has been that no comprehensive dossier has been compiled on the vaccine” as this is 
incorrect. Detailed information dossiers have been prepared for the I-2 ND vaccine 
produced in a number of countries. The dossiers included in vitro and in vivo safety test 
results. The findings presented in this paper provides further evidence that the I-2 ND 




Please change “Dr Spradbrow” to “Professor Spradbrow”.○
 
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Newcastle disease prevention and control including ND vaccine production, 
quality assurance and field use.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 11 Jun 2021
Gil Domingue, GALVmed, Pentlands Science Park, Midlothian, Scotland, UK 
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2. Last sentence: please reword to indicate that this current study provides additional and 
definitive evidence that the I-2 ND strain is safe to use. 
 
We do not find our Abstract final sentence is very different from that suggested. Also we are 
restricted to 300 words. We think the point is that our study was conducted to be definitive from 
an international regulatory perspective. 
 
3. Please revise the statement “Unfortunately the behaviour of village birds is suited to 
disease spread” etc. 
 
Accepted; Dr Msoffe, one of our reviewers and lead author on the paper we reference here, has 
suggested we rewrite this as “the behaviour of the village birds make them prone to or exposes 
them to the spread of ND and other similar diseases”. We will revise this.  
 
4. Please revise the statement “ND I-2 vaccine use has also been allowed in these low-
middle income countries because local registration requirements are relatively relaxed, etc. 
 
GALVmed was advised by its independent Technical Subcommitee comprised of international 
experts. who informed us that to their knowledge at the time, "no comprehensive dossier of an 
international regulatory standard had been compiled on the vaccine". We can revise the text. 
 
5. Discussion.Please change “Dr Spradbrow” to “Professor Spradbrow”. 
 
Accepted.  
Competing Interests: No competing interests were disclosed.
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